Which has higher earnings and valuation, LLY or AMGN?

Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eli Lilly and Company $65.18B 17.61 $20.64B $28.15 43.30 Amgen $36.75B 5.40 $7.71B $14.37 25.61

Is LLY or AMGN more profitable?

Eli Lilly and Company has a net margin of 34.98% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Eli Lilly and Company's return on equity. Company Net Margins Return on Equity Return on Assets Eli Lilly and Company 34.98% 105.77% 23.76% Amgen 20.96% 137.41% 13.28%

Does the media prefer LLY or AMGN?

In the previous week, Eli Lilly and Company had 84 more articles in the media than Amgen. MarketBeat recorded 124 mentions for Eli Lilly and Company and 40 mentions for Amgen. Eli Lilly and Company's average media sentiment score of 1.00 beat Amgen's score of 0.98 indicating that Eli Lilly and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 81 Very Positive mention(s) 12 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Amgen 29 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, LLY or BIIB?

Eli Lilly and Company has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eli Lilly and Company $65.18B 17.61 $20.64B $28.15 43.30 Biogen $9.89B 2.99 $1.29B $9.32 21.50

Does the media favor LLY or BIIB?

In the previous week, Eli Lilly and Company had 107 more articles in the media than Biogen. MarketBeat recorded 124 mentions for Eli Lilly and Company and 17 mentions for Biogen. Eli Lilly and Company's average media sentiment score of 1.00 beat Biogen's score of 0.66 indicating that Eli Lilly and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 81 Very Positive mention(s) 12 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Biogen 9 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, LLY or INCY?

Eli Lilly and Company has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eli Lilly and Company $65.18B 17.61 $20.64B $28.15 43.30 Incyte $5.14B 4.56 $1.29B $7.08 16.56

Does the media favor LLY or INCY?

In the previous week, Eli Lilly and Company had 114 more articles in the media than Incyte. MarketBeat recorded 124 mentions for Eli Lilly and Company and 10 mentions for Incyte. Eli Lilly and Company's average media sentiment score of 1.00 beat Incyte's score of 0.79 indicating that Eli Lilly and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 81 Very Positive mention(s) 12 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Incyte 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, NVDA or LLY?

NVIDIA has higher revenue and earnings than Eli Lilly and Company. NVIDIA is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NVIDIA $215.94B 22.88 $120.07B $6.53 31.26 Eli Lilly and Company $65.18B 17.61 $20.64B $28.15 43.30

Does the media favor NVDA or LLY?

In the previous week, NVIDIA had 173 more articles in the media than Eli Lilly and Company. MarketBeat recorded 297 mentions for NVIDIA and 124 mentions for Eli Lilly and Company. Eli Lilly and Company's average media sentiment score of 1.00 beat NVIDIA's score of 0.69 indicating that Eli Lilly and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NVIDIA 158 Very Positive mention(s) 32 Positive mention(s) 63 Neutral mention(s) 36 Negative mention(s) 8 Very Negative mention(s) Positive Eli Lilly and Company 81 Very Positive mention(s) 12 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to VKTX or LLY?

In the previous week, Eli Lilly and Company had 117 more articles in the media than Viking Therapeutics. MarketBeat recorded 124 mentions for Eli Lilly and Company and 7 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 1.00 beat Viking Therapeutics' score of 0.33 indicating that Eli Lilly and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eli Lilly and Company 81 Very Positive mention(s) 12 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Eli Lilly and Company (LLY) Competitors

$1,218.76 -16.80 (-1.36%)

Closing price 03:59 PM Eastern

Extended Trading

$1,220.28 +1.52 (+0.12%)

As of 07:59 PM Eastern

Compare

LLY vs. AMGN, BIIB, INCY, NVDA, and VKTX

Should you buy Eli Lilly and Company stock or one of its competitors? MarketBeat compares Eli Lilly and Company with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eli Lilly and Company include Amgen (AMGN), Biogen (BIIB), Incyte (INCY), NVIDIA (NVDA), and Viking Therapeutics (VKTX).

How does Eli Lilly and Company compare to Amgen?

Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Eli Lilly and Company has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Eli Lilly and Company has a net margin of 34.98% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Eli Lilly and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Amgen	20.96%	137.41%	13.28%

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by company insiders. Comparatively, 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	17.61	$20.64B	$28.15	43.30
Amgen	$36.75B	5.40	$7.71B	$14.37	25.61

Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.6%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.7%. Eli Lilly and Company pays out 24.6% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and Company has raised its dividend for 11 consecutive years and Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Eli Lilly and Company currently has a consensus target price of $1,255.89, indicating a potential upside of 3.05%. Amgen has a consensus target price of $355.73, indicating a potential downside of 3.33%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, equities analysts clearly believe Eli Lilly and Company is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

In the previous week, Eli Lilly and Company had 84 more articles in the media than Amgen. MarketBeat recorded 124 mentions for Eli Lilly and Company and 40 mentions for Amgen. Eli Lilly and Company's average media sentiment score of 1.00 beat Amgen's score of 0.98 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	81 Very Positive mention(s)	12 Positive mention(s)	24 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Amgen	29 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Eli Lilly and Company beats Amgen on 15 of the 19 factors compared between the two stocks.

How does Eli Lilly and Company compare to Biogen?

Eli Lilly and Company (NYSE:LLY) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Eli Lilly and Company had 107 more articles in the media than Biogen. MarketBeat recorded 124 mentions for Eli Lilly and Company and 17 mentions for Biogen. Eli Lilly and Company's average media sentiment score of 1.00 beat Biogen's score of 0.66 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	81 Very Positive mention(s)	12 Positive mention(s)	24 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Biogen	9 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Eli Lilly and Company presently has a consensus price target of $1,255.89, indicating a potential upside of 3.05%. Biogen has a consensus price target of $218.15, indicating a potential upside of 8.88%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Biogen	2 Sell rating(s)	12 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.52

Eli Lilly and Company has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	17.61	$20.64B	$28.15	43.30
Biogen	$9.89B	2.99	$1.29B	$9.32	21.50

Eli Lilly and Company has a net margin of 34.98% compared to Biogen's net margin of 13.81%. Eli Lilly and Company's return on equity of 105.77% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Biogen	13.81%	12.83%	8.01%

Eli Lilly and Company has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Biogen has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Eli Lilly and Company beats Biogen on 14 of the 17 factors compared between the two stocks.

How does Eli Lilly and Company compare to Incyte?

Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Eli Lilly and Company had 114 more articles in the media than Incyte. MarketBeat recorded 124 mentions for Eli Lilly and Company and 10 mentions for Incyte. Eli Lilly and Company's average media sentiment score of 1.00 beat Incyte's score of 0.79 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	81 Very Positive mention(s)	12 Positive mention(s)	24 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Incyte	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eli Lilly and Company presently has a consensus price target of $1,255.89, suggesting a potential upside of 3.05%. Incyte has a consensus price target of $108.20, suggesting a potential downside of 7.73%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, equities research analysts clearly believe Eli Lilly and Company is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36

Eli Lilly and Company has a net margin of 34.98% compared to Incyte's net margin of 26.71%. Eli Lilly and Company's return on equity of 105.77% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Incyte	26.71%	26.66%	19.77%

Eli Lilly and Company has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Eli Lilly and Company has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	17.61	$20.64B	$28.15	43.30
Incyte	$5.14B	4.56	$1.29B	$7.08	16.56

Summary

Eli Lilly and Company beats Incyte on 14 of the 17 factors compared between the two stocks.

How does Eli Lilly and Company compare to NVIDIA?

NVIDIA (NASDAQ:NVDA) and Eli Lilly and Company (NYSE:LLY) are related large-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

NVIDIA pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.6%. NVIDIA pays out 15.3% of its earnings in the form of a dividend. Eli Lilly and Company pays out 24.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. NVIDIA has increased its dividend for 1 consecutive years and Eli Lilly and Company has increased its dividend for 11 consecutive years. Eli Lilly and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

NVIDIA has a net margin of 62.97% compared to Eli Lilly and Company's net margin of 34.98%. Eli Lilly and Company's return on equity of 105.77% beat NVIDIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NVIDIA	62.97%	96.94%	72.16%
Eli Lilly and Company	34.98%	105.77%	23.76%

65.3% of NVIDIA shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 3.9% of NVIDIA shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NVIDIA has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

NVIDIA has higher revenue and earnings than Eli Lilly and Company. NVIDIA is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NVIDIA	$215.94B	22.88	$120.07B	$6.53	31.26
Eli Lilly and Company	$65.18B	17.61	$20.64B	$28.15	43.30

In the previous week, NVIDIA had 173 more articles in the media than Eli Lilly and Company. MarketBeat recorded 297 mentions for NVIDIA and 124 mentions for Eli Lilly and Company. Eli Lilly and Company's average media sentiment score of 1.00 beat NVIDIA's score of 0.69 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NVIDIA	158 Very Positive mention(s)	32 Positive mention(s)	63 Neutral mention(s)	36 Negative mention(s)	8 Very Negative mention(s)	Positive
Eli Lilly and Company	81 Very Positive mention(s)	12 Positive mention(s)	24 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

NVIDIA presently has a consensus target price of $303.84, suggesting a potential upside of 48.85%. Eli Lilly and Company has a consensus target price of $1,255.89, suggesting a potential upside of 3.05%. Given NVIDIA's stronger consensus rating and higher possible upside, equities analysts clearly believe NVIDIA is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NVIDIA	0 Sell rating(s)	3 Hold rating(s)	48 Buy rating(s)	3 Strong Buy rating(s)	3.00
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

Summary

NVIDIA beats Eli Lilly and Company on 13 of the 20 factors compared between the two stocks.

How does Eli Lilly and Company compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Eli Lilly and Company (NYSE:LLY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

In the previous week, Eli Lilly and Company had 117 more articles in the media than Viking Therapeutics. MarketBeat recorded 124 mentions for Eli Lilly and Company and 7 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 1.00 beat Viking Therapeutics' score of 0.33 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eli Lilly and Company	81 Very Positive mention(s)	12 Positive mention(s)	24 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

Viking Therapeutics presently has a consensus price target of $93.60, indicating a potential upside of 134.23%. Eli Lilly and Company has a consensus price target of $1,255.89, indicating a potential upside of 3.05%. Given Viking Therapeutics' higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

Viking Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Eli Lilly and Company	$65.18B	17.61	$20.64B	$28.15	43.30

Eli Lilly and Company has a net margin of 34.98% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 105.77% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Eli Lilly and Company	34.98%	105.77%	23.76%

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Eli Lilly and Company News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LLY vs. The Competition

Export

Metric	Eli Lilly and Company	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$1.16T	$338.94B	$6.99B	$23.55B
Dividend Yield	0.56%	2.67%	2.67%	4.01%
P/E Ratio	43.30	29.91	22.40	28.11
Price / Sales	17.61	5.48	534.05	21.17
Price / Cash	49.15	14.40	49.24	25.14
Price / Book	43.42	8.50	10.83	4.74
Net Income	$20.64B	$11.61B	$3.56B	$1.07B
7 Day Performance	2.23%	1.97%	0.81%	-0.70%
1 Month Performance	6.04%	9.08%	5.61%	1.64%
1 Year Performance	56.67%	29.34%	32.58%	16.02%

Eli Lilly and Company Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LLY Eli Lilly and Company	4.5802 of 5 stars	$1,218.76 -1.4%	$1,252.48 +2.8%	+59.6%	$1.16T	$65.18B	43.30	50,000	Trending News Analyst Forecast
AMGN Amgen	4.0178 of 5 stars	$374.15 flat	$355.50 -5.0%	+25.7%	$201.93B	$36.75B	26.04	31,500	Trending News Analyst Forecast
BIIB Biogen	3.9171 of 5 stars	$216.12 flat	$217.41 +0.6%	+58.1%	$31.91B	$9.89B	23.19	7,500	Analyst Forecast
INCY Incyte	3.7503 of 5 stars	$116.86 flat	$107.85 -7.7%	+75.5%	$23.35B	$5.14B	16.51	2,844	Analyst Forecast
NVDA NVIDIA	4.9952 of 5 stars	$194.83 flat	$303.84 +56.0%	+24.5%	$4.71T	$215.94B	29.84	42,000	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:LLY) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Competitors

LLY vs. AMGN, BIIB, INCY, NVDA, and VKTX

How does Eli Lilly and Company compare to Amgen?

Summary

How does Eli Lilly and Company compare to Biogen?

Summary

How does Eli Lilly and Company compare to Incyte?

Summary

How does Eli Lilly and Company compare to NVIDIA?

Summary

How does Eli Lilly and Company compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LLY vs. The Competition

Eli Lilly and Company Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eli Lilly and Company (LLY) Competitors

LLY vs. AMGN, BIIB, INCY, NVDA, and VKTX

How does Eli Lilly and Company compare to Amgen?

Which has more volatility & risk, LLY or AMGN?

Is LLY or AMGN more profitable?

Do institutionals & insiders have more ownership in LLY or AMGN?

Which has higher earnings and valuation, LLY or AMGN?

Is LLY or AMGN a better dividend stock?

Do analysts recommend LLY or AMGN?

Does the media prefer LLY or AMGN?

Summary

How does Eli Lilly and Company compare to Biogen?

Does the media favor LLY or BIIB?

Do analysts rate LLY or BIIB?

Which has preferable valuation and earnings, LLY or BIIB?

Is LLY or BIIB more profitable?

Which has more risk & volatility, LLY or BIIB?

Do insiders and institutionals believe in LLY or BIIB?

Summary

How does Eli Lilly and Company compare to Incyte?

Does the media favor LLY or INCY?

Do institutionals and insiders have more ownership in LLY or INCY?

Do analysts prefer LLY or INCY?

Is LLY or INCY more profitable?

Which has more risk & volatility, LLY or INCY?

Which has stronger earnings & valuation, LLY or INCY?

Summary

How does Eli Lilly and Company compare to NVIDIA?

Is NVDA or LLY a better dividend stock?

Is NVDA or LLY more profitable?

Do institutionals & insiders have more ownership in NVDA or LLY?

Which has more risk & volatility, NVDA or LLY?

Which has stronger earnings & valuation, NVDA or LLY?

Does the media favor NVDA or LLY?

Do analysts rate NVDA or LLY?

Summary

How does Eli Lilly and Company compare to Viking Therapeutics?

Does the media refer more to VKTX or LLY?

Do analysts rate VKTX or LLY?

Which has more risk and volatility, VKTX or LLY?

Do institutionals and insiders believe in VKTX or LLY?

Which has preferable valuation and earnings, VKTX or LLY?

Is VKTX or LLY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LLY vs. The Competition

Eli Lilly and Company Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools